Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
The Maire - EuroChem Case: Three Lessons for Global Business 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
SOUTH PLAINFIELD, N.J., May 17, 2017 -- Advanced Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today the appointment of Howard McLeod, PharmD to its advisory board. Dr. McLeod brings more than 18 years of experience to Admera Health and is an internationally recognized expert on pharmacogenomics and the role that genetic differences have in individual responses to cancer therapy.
Dr. McLeod has a long list of accolades. He is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, chairs multiple committees on cancer care, the National Human Genome Research Institute (NHGRI), the eMERGE Network’s External Scientific Panel, and a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. In addition, Dr. McLeod has published over 500 peer reviewed papers on pharmacogenomics, applied therapeutics, and clinical pharmacology.
“Howard McLeod is an outstanding addition to our advisory board,” stated Guanghui Hu, PhD, CEO and President of Admera Health. “His expertise and level of experience in pharmacogenomics will contribute to further our mission of providing innovative, personalized solutions. We are especially looking forward to him providing guidance as we move our pharmacogenomics expertise further into supportive care for cancer patients.”
Admera Health offers the most comprehensive pharmacogenomics testing services available, its PGxOne™ Plus test interrogates 50 genes with coverage of ~200 genetic variants and provides recommendation on over 300 drugs.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
